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Abstract
Background: Patients suffering from osteoporosis show an increased number of adipocytes in their bone marrow,
concomitant with a reduction in the pool of human mesenchymal stem cells (hMSCs) that are able to differentiate
into osteoblasts, thus leading to suppressed osteogenesis.
Methods: In order to be able to interfere with this process, we have investigated in-vitro culture conditions
whereby adipogenic differentiation of hMSCs is impaired and osteogenic differentiation is promoted. By means of
gene expression microarray analysis, we have investigated genes which are potential targets for prevention of fat
cell differentiation.
Results: Our data show that BMP2 promotes both adipogenic and osteogenic differentiation of hMSCs, while
transforming growth factor beta (TGFβ) inhibits differentiation into both lineages. However, when cells are cultured
under adipogenic differentiation conditions, which contain cAMP-enhancing agents such as IBMX of PGE2, TGFβ
promotes osteogenic differentiation, while at the same time inhibiting adipogenic differentiation. Gene expression
and immunoblot analysis indicated that IBMX-induced suppression of HDAC5 levels plays an important role in the
inhibitory effect of TGFβ on osteogenic differentiation. By means of gene expression microarray analysis, we have
investigated genes which are downregulated by TGFβ under adipogenic differentiation conditions and may therefore be
potential targets for prevention of fat cell differentiation. We thus identified nine genes for which FDA-approved drugs
are available. Our results show that drugs directed against the nuclear hormone receptor PPARG, the metalloproteinase
ADAMTS5, and the aldo-keto reductase AKR1B10 inhibit adipogenic differentiation in a dose-dependent manner,
although in contrast to TGFβ they do not appear to promote osteogenic differentiation.
Conclusions: The approach chosen in this study has resulted in the identification of new targets for inhibition of fat cell
differentiation, which may not only be relevant for prevention of osteoporosis, but also of obesity.
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Background
Human mesenchymal stem cells (hMSCs) from bone mar-
row have the ability to differentiate into cells from multiple
lineages, including osteoblasts and adipocytes. The com-
mitment of hMSCs towards either the osteogenic or adipo-
genic lineage depends on the local availability of growth
factors and hormones, which are able to activate lineage-
specific transcriptional regulators [1]. Patients suffering
from osteoporosis show an increased number of adipocytes
in their bone marrow, concomitant with a reduction in the
pool of hMSCs that are able to differentiate into osteo-
blasts, thus leading to suppressed osteogenesis [2, 3]. It is
still unclear to what extent this age-related increase in dif-
ferentiation of hMSCs towards adipocytes results from
intrinsic changes in the stem cells or from alterations in
the microenvironment of the bone marrow [1, 4]. These
observations have recently stirred increasing interest in
anabolic therapies for osteoporosis, whereby osteogenic
differentiation of hMSCs is stimulated by preventing
adipogenic differentiation [5, 6].
Most information about the signaling pathways that
are required for osteogenic and adipogenic differenti-
ation of hMSCs has come from in-vitro studies,
whereby cells are treated with specific combinations of
growth factors and hormones [7]. Differentiation into
both lineages requires treatment of monolayer cells
with dexamethasone (DEX) and is enhanced by the
presence of bone morphogenetic proteins (BMPs).
Osteogenic differentiation is obtained by the additional
presence of ascorbate and β-glycerophosphate, whereas
adipogenic differentiation requires treatment with
insulin, 3-isobutyl-1-methylxanthine (IBMX), and the
PPARG activator rosiglitazone. Our previous data have
indicated that under these experimental conditions at
least 75 % of the hMSCs differentiate into either osteo-
blasts or adipocytes [7].
Activation of the RUNX2 nuclear transcription factor ap-
pears to be essential for the osteogenic pathway of hMSCs,
while the adipogenic pathway requires the transcriptional
activity of the PPARG nuclear hormone receptor [1]. Evi-
dence has been presented that transcriptional regulators
promoting differentiation into one of these lineages actively
suppress differentiation into the other lineage [8]. It has
therefore been postulated that a reciprocal relationship ex-
ists between the osteogenic and adipogenic pathways, im-
plying that impaired adipogenic differentiation of hMSCs
may result in enhanced osteogenic differentiation [3].
Multiple regulators are known that affect the choice
between the osteogenic and adipogenic lineage. Most not-
ably, activation of the WNT/β-catenin pathway promotes
osteogenic differentiation and inhibits adipogenic differen-
tiation of hMSCs [9]. BMP enhances the outgrowth of
both osteoblasts and adipocytes, while the related cytokine
transforming growth factor beta (TGFβ) inhibits both
osteogenic and adipogenic differentiation, at least when
tested under these in-vitro conditions [10, 11]. Moreover,
Kim et al. [12] have shown that cAMP-activated protein
kinases regulate the differentiation choice of hMSCs
between osteogenesis and adipogenesis.
In order to find drugs affecting the choice between
osteogenic and adipogenic differentiation of hMSCs, we
have optimized the adipogenic culture conditions in such a
way that, within the same culture, a fraction of the cells
differentiates into osteoblasts and another fraction into adi-
pocytes. Our results show that addition of TGFβ to these
cultures fully blocks adipogenic differentiation but, surpris-
ingly, enhances osteogenic differentiation. Analysis of the
individual components in the culture medium showed
that the presence of the phosphodiesterase inhibitor
IBMX, which stabilizes cAMP levels in the cell, con-
verted TGFβ from an inhibitor to an enhancer of osteo-
genic differentiation.
Based on these observations we have set up a gene ex-
pression microarray experiment to identity genes that
under these optimized adipogenic culture conditions are
downregulated by TGFβ. The genes identified in this
way seem to play an important role in adipogenesis,
since inhibitors of the corresponding proteins were
found to be able to block adipogenic differentiation of
hMSCs. Some of these inhibitors have already received
FDA approval for the treatment of various diseases, and
may therefore be good candidates for therapeutic drug
repurposing in order to treat patients suffering from
such diseases as obesity and osteoporosis.
Methods
Culture and differentiation of hMSCs
hMSCs harvested from normal human bone marrow were
purchased from Lonza (Walkersville, MD, USA) at passage
2. Cells were expanded for no more than five passages in
“mesenchymal stem cell growth medium” (MSCGM;
Lonza) at 37 °C in a humidified atmosphere containing
7.5 % CO2. Studies were performed with hMSCs from
three different donors, encoded 5F0138, 6F4085, and
7F3458.
For differentiation experiments, 4.0 × 104 cells per cm2
were seeded in high-glucose-containing Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % fetal bovine serum (a selected lot from Lonza), 100
U/ml penicillin, and 100 μg/ml streptomycin. This
medium will be further referred to as “proliferation
medium” (PM). The next day, cells were switched to
either osteogenic or adipogenic differentiation medium.
Cells treated with PM were used as negative controls.
Osteogenic differentiation medium (ODM) was com-
posed of PM supplemented with 10−7 M DEX, 0.2 mM
ascorbate, and 10 mM β-glycerophosphate. Adipogenic
differentiation medium (ADM) was composed of PM
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supplemented with 10−6 M DEX, 10 μg/ml insulin (R&D
Systems, Minneapolis, MN, USA), 10−7 M rosiglitazone
(Sigma-Aldrich, St. Louis, MO, USA), and 500 μM
IBMX (Sigma-Aldrich). Unless indicated otherwise,
recombinant human TGFβ1 and BMP2 (both from R&D
Systems) were used at concentrations of 2 ng/ml and
125 ng/ml, respectively. Prostaglandin E2 (PGE2),
Batimastat, and Zopolrestat (Sigma-Aldrich) were used
at the indicated concentrations. Media were refreshed
every 3–4 days.
Alkaline phosphatase assays
To quantify alkaline phosphatase (ALP) enzymatic activ-
ity as a measure of osteogenic differentiation, hMSCs
were seeded in 96-well tissue culture plates as already
described, after which cells were differentiated for 7 days
in osteogenic differentiation medium. ALP enzymatic ac-
tivity was quantified by measuring the formation of p-ni-
trophenol from p-nitrophenyl phosphate (PNPP; Sigma-
Aldrich), as described previously [13]. ALP enzymatic
activity was corrected for differences in cell number, as
determined by a Neutral Red assay. Cells were incubated
with Neutral Red dye diluted in PBS for 1 hour at 37 °C.
After washing with PBS, the dye was extracted from the
cells using 0.05 M NaH2PO4 in 50 % EtOH, after which
the absorbance was measured at 540 nm.
For histochemical analysis of ALP activity, cells were
seeded in 48-well tissue culture plates and differentiated for
7 days in osteogenic differentiation medium. Subsequently,
cells were fixed in 3.7 % formaldehyde/PBS for 10 min at
22 °C. After washing with PBS, cells were incubated for
1 hour at 37 °C in a mixture of 0.1 mg/ml naphtol AS-
MX phosphate (Sigma-Aldrich), 0.5 %N,N-dimethylfor-
mamide, 2 mM MgCl2, and 0.6 mg/ml Fast Blue BB salt
(Sigma-Aldrich) in 0.1 M Tris–HCl, pH 8.5.
Mineralization assay
To measure calcium deposition in the extracellular
matrix, hMSCs were seeded in 24-well tissue culture
plates and cultured for 13 days under osteogenic or
adipogenic differentiation conditions, as indicated. Cells
were subsequently washed twice with PBS after which
calcium was extracted from the extracellular matrix by
treatment with 150 μl of 0.5 M HCl. Calcium concen-
trations were measured in a colorimetric assay using o-
cresolphtalein complexone as a chromogenic agent,
according to the protocol provided by the manufac-
turer (Sigma-Aldrich).
Oil Red O staining and Triglyceride assay
To quantify adipogenic differentiation, lipid droplets
were stained in mature adipocytes obtained after treat-
ment of hMSCs for 9 days in adipogenic differentiation
medium. Cells were first washed twice with PBS, fixed
for 30 min with 1 % formaldehyde in PBS, and then
washed once with water and twice with 60 % isopropa-
nol. Cells were then stained for 1 hour with 0.3 % w/v
Oil Red O (Sigma-Aldrich) in 60 % isopropanol. Subse-
quently, cells were washed once with 60 % isopropanol
and twice with distilled water. For quantification of Oil
Red O staining, samples were treated with 100 % iso-
propanol and absorbance was measured at 530 nm.
The amount of triglycerides stored in lipid droplets
of mature adipocytes was quantified after treatment of
hMSCs for 9 days in adipogenic differentiation
medium. Cells in 96-well tissue culture plates were
washed twice with PBS. Triglycerides were extracted
from the lipid droplets by freezing the cells in 50 μl of
a buffer containing 25 mM Tris–HCl (pH 7.5) and
1 mM EDTA, followed by addition of 40 μl tert-buta-
nol and 10 μl methanol. Samples were heat-dried at
55 °C, after which they were resuspended in Triglycer-
ides LiquiColor® mono reagents (HUMAN GmbH,
Wiesbaden, Germany). Triglycerides were quantified
by measuring the absorbance at 490 nm.
RNA isolation and real-time quantitative RT-PCR
RNA was isolated as described by Piek et al. [13]. For
cDNA synthesis, 1 μg of total RNA was reverse tran-
scribed using random hexamer primers and SUPER-
SCRIPT™ II reverse transcriptase (Invitrogen, Carlsbad,
CA, USA). Subsequently, cDNA was amplified in a
quantitative real-time PCR, performed using Power
SYBR Green® PCR Mastermix (Applied Biosystems,
Foster City, CA, USA) on an Applied Biosystems 7500
Real-time Fast PCR System. For each gene, PCR was
carried out in duplicate and mean expression values
were calculated relative to the mean expression level of
the housekeeping gene RPS27A (ribosomal protein
S27a). Human gene-specific PCR primers used included
the following:
Histone deacetylase 5 (HDAC5)-FW:
5′-ATGACAACGGGAACTTCTTTCC-3′.










Ribosomal protein S27a (RPS27A)-FW:
5′-GTTAAGCTGGCTGTCCTGAAA-3′.
Ribosomal protein S27a (RPS27A)-RV:
5′-CATCAGAAGGGCACTCTCG-3′.
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Immunoblotting
hMSCs were seeded at 4.0 × 104 cells per cm2 in six-well
plates and cultured for 24 hours in the indicated differen-
tiation media. Cells were then lysed in 250 μl of RIPA lysis
buffer per well. Then 5 μl of reducing sample buffer was
added to 25 μl of lysate, heated to 95 °C, and subsequently
loaded onto an 8 % SDS-PAGE gel. HDAC5 was detected
on blots using a goat polyclonal anti-HDAC5 antibody
(G-18, 1/200 dilution) raised against the N-terminus of
human HDAC5 (sc-5250; Santa Cruz Biotechnology,
Dallas, TX, USA), followed by an HRP-labeled polyclonal
secondary antibody. Antibodies against α-tubulin (Sigma)
served as a loading control.
Gene expression microarray analysis
To identify genes that are regulated during osteogenic
and adipogenic differentiation of hMSCs, a total of 54
samples (each containing 800,000 cells/ 20 cm2) were
seeded in PM and grown for 24 hours. Subsequently the
medium was exchanged for differentiation medium, now
consisting of PM with 10−6 M DEX, 10 μg/ml insulin, 10
−7 M rosiglitazone, and 50 ng/ml BMP2 (B). In addition,
either 5 ng/ml TGFβ (BT), or 250 μM IBMX (BI), or
5 ng/ml TGFβ and 250 μM IBMX (BTI) were added.
Samples were incubated for either 0, 1, 2, 3, or 7 days.
Experiments for each group and time point were carried
out as three biological replicates, while the untreated
control group (time 0) consisted of six samples. RNA
was isolated as already described, and hybridized onto
Affymetrix HGU 133 plus 2.0 microarrays according to
existing protocols [13].
Microarray data were analyzed with the R language for
statistical computing using appropriate Bioconductor
packages (http://bioconductor.org/) for reading, normal-
izing, and statistically evaluating the data, followed by
annotation of the gene sets and integration of parallel
data sources. Briefly, the analysis started with a careful
quality assessment of the dataset using the automatic R
pipeline AffymetrixQC [14], which was customized and
run locally. All 54 microarrays passed the quality control
and were included in the analysis, consisting of robust
microarray analysis (RMA) normalization [15], followed by
statistical analysis to find differentially expressed genes
using Linear Models for Microarray Data (LIMMA) [16],
and subsequent functional annotation and enrichment
analysis using the online resource Database for Annotation,
Visualization and Integrated Discovery (DAVID) [17, 18].
Finally, the list of differentially expressed genes for the con-
trasts of interest was crossed with the information from
the DrugBank database [19] in order to derive the final list
of candidate genes for experimental testing. All R scripts
used for this analysis are available upon request. Current
microarray data have been deposited in NCBI’s Gene
Expression Omnibus [GEO:GSE84500] (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE84500).
Statistical analysis
Student’s t test was used for statistical comparisons.
Numeric data are represented as mean ± standard devi-
ation of triplicate experiments, unless stated otherwise.
Results
TGFβ induces hMSCs to switch from adipogenic to
osteogenic differentiation
BMPs have been described as positive regulators of both
osteogenesis and adipogenesis [8, 10]. In order to study
the effect of BMP2 on differentiation of hMSCs in more
detail, we cultured these cells in either osteogenic differ-
entiation medium or adipogenic differentiation medium
in the absence and presence of BMP2. Figure 1a shows
that addition of BMP2 has only a small stimulatory
effect on adipogenic differentiation of hMSCs, as mea-
sured by the amount of the triglyceride production. On the
other hand, BMP2 strongly enhanced osteogenic differenti-
ation, as indicated by increased ALP activity (Fig. 1b).
The role of TGFβ in adipogenic and osteogenic differen-
tiation of hMSCs is still unclear. Figure 1a also shows that
adding TGFβ to adipogenic differentiation medium blocks
adipogenic differentiation of hMSCs in a dose-dependent
manner, both in the absence and additional presence of
BMP2. Figure 1b shows that addition of TGFβ to osteo-
genic differentiation medium results in a similar inhibition
of osteogenic differentiation, both in agreement with
previous data [10, 11]. However, when hMSCs are treated
with adipogenic differentiation medium (which contains a
10-fold higher concentration of DEX than osteogenic dif-
ferentiation medium) in combination with BMP2, a frac-
tion of the cells will differentiate into bone cells and a
fraction into fat cells within the same well, as shown in
Fig. 1c by histological staining. Addition of TGFβ under
these conditions resulted is a dose-dependent increase in
the number of ALP-positive bone cells, with a concomi-
tant reduction in Oil Red O-positive fat cells. These data
show that TGFβ blocks bone cell differentiation under
osteogenic differentiation conditions, but enhances bone
cell differentiation under adipogenic differentiation condi-
tions. It can therefore be concluded that, under the experi-
mental conditions used in Fig. 1c, TGFβ induces a switch
from adipogenic to osteogenic differentiation.
IBMX is a critical component in the TGFβ-mediated switch
in cell fate
In order to investigate which component of the adipogenic
differentiation medium allows osteogenic differentiation
in the presence of TGFβ, we added the adipogenic
differentiation medium components insulin, IBMX, and
rosiglitazone successively to hMSCs grown in osteogenic
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differentiation medium with BMP2 and TGFβ. Figure 2a
shows that the inhibition of osteogenic differentiation by
TGFβ could not be prevented by insulin or rosiglitazone,
but was largely overcome upon addition of IBMX. A
parallel experiment showed that omission of IBMX from
adipogenic differentiation medium was sufficient to pre-
vent the TGFβ-induced enhancement of osteogenic differ-
entiation, while removal of insulin or rosiglitazone was
without effect (Fig. 2b).
IBMX is a phosphodiesterase inhibitor, which prevents
degradation of cAMP. In order to show that enhanced
cAMP levels play a role in the TGFβ-mediated switch in
cell fate, we tested the effect of PGE2, a known activator
of adenylate cyclase. Figure 2c shows that PGE2 is able
to overcome TGFβ-induced inhibition of osteogenic dif-
ferentiation of hMSCs in a dose-dependent manner, to a
similar extent as IBMX.
Osteogenic differentiation requires not only matrix mat-
uration, as indicated by alkaline phosphatase expression,
but also matrix mineralization, as indicated by calcium
deposition. Figure 2d shows that under osteogenic differ-
entiation conditions BMP is required for calcium depos-
ition by hMSCs, while both BMP and TGFβ are required
under adipogenic differentiation. These data show TGFβ
is able to induce fully differentiated, mineralized osteo-
blasts under adipogenic differentiation conditions.
IBMX suppresses HDAC5 expression
Previous studies [20] have shown that TGFβ-mediated
inhibition of osteogenic differentiation can be overcome
by trichostatin A, an inhibitor of class I and II mammalian
histone deacetylases (HDACs). We confirmed this obser-
vation upon incubating hMSCs in osteogenic differenti-
ation medium with BMP2 and TGFβ (data not shown).
Kang et al. [20] have presented evidence that HDAC4/5
can interact with TGFβ-activated SMAD3, resulting in a
complex that represses transcription of the bone marker
gene osteocalcin (BGLAP). In human adipose-derived
mesenchymal stem cells, trichostatin A impaired PPARG
activity, at least under osteogenic differentiation condi-
tions [21]. Still, the role of HDACs in adipogenesis is far
from clear, since HDAC inhibitors may either enhance or
inhibit adipogenic differentiation [22].
We have studied the expression of HDAC5 under con-
ditions that TGFβ enhances osteogenic differentiation of
hMSCs. Figure 3a shows that HDAC5 mRNA levels are
slightly upregulated 24–48 hours after addition of osteo-
genic differentiation medium, particularly in the pres-
ence of BMP2 and TGFβ (OBT). A strong reduction in
HDAC5 gene expression was observed when IBMX was
added to the medium (OBTI), however, thus creating
conditions under which adipogenic differentiation is pre-
vented and osteogenic differentiation is promoted. Less
reduction in HDAC5 mRNA levels was observed in
adipogenic differentiation medium alone. We could not
detect mRNA expression of HDAC4 in these cells.
Figure 3b shows that HDAC5 levels are similarly regu-
lated at the protein level. Western blot analysis revealed
Fig. 1 Effect of TGFβ on adipogenic and osteogenic differentiation
of hMSCs. a Triglyceride production by hMSCs, 9 days after incubation
with adipogenic differentiation medium in the absence (white shading)
and presence (black shading) of 125 ng/ml BMP2 and increasing
concentrations of TGFβ1. The enhancing effect of BMP2 is not
significant, while the inhibitory effect of TGFβ is significant (p < 0.01)
above 1 ng/ml. b Alkaline phosphatase (ALP) activity of hMSCs, 7 days
after incubation with osteogenic differentiation medium in the
absence (white shading) and presence (black shading) of 125 ng/ml
BMP2 and increasing concentrations of TGFβ1. Enhancing effect of
BMP2 is significant (p < 0.01) at all data points, while the inhibitory
effect of TGFβ is significant (p < 0.01) above 1 ng/ml. c TGFβ-induced
switch from adipogenic to osteogenic differentiation. ALP staining
(after 7 days) and Oil Red O (ORO) staining (after 9 days) following
incubation of hMSCs in adipogenic differentiation medium containing
125 ng/ml BMP2 and the indicated concentrations of TGFβ1. BMP
bone morphogenetic protein, TGFβ transforming growth factor beta
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the highest expression level in hMSCs treated with
osteogenic differentiation medium containing BMP2 and
TGFβ (OBT), whereas almost no protein was detected
in the additional presence of IBMX (OBTI). These data
indicate that under conditions whereby TGFβ enhances
osteogenic differentiation, no HDAC5 is available to
prevent expression of bone specific genes.
Altered gene expression during TGFβ-mediated switch in
cell fate
The presented data show that, upon incubation of hMSCs
in adipogenic differentiation medium containing BMP2
and IBMX, a fraction of the cells will differentiate into
ALP-positive bone cells and a fraction into Oil Red O-
positive fat cells. Subsequent addition of TGFβ reduces
the number of fat cells and enhances the number of bone
cells in a dose-dependent manner (see Fig. 1c). This obser-
vation implies that under these experimental conditions
addition of TGFβ will stimulate the expression of osteo-
blast genes and reduce the expression of adipocyte genes.
In order to identify genes involved in this lineage switch,
we performed gene expression microarray analysis on
hMSCs, treated for 1, 2, 3, or 7 days with differentiation
medium containing DEX, insulin, and rosiglitazone, using
Fig. 2 cAMP regulators control TGFβ-induced osteogenic differentiation of hMSCs. Osteogenic differentiation was measured by ALP activity and
corrected for the level of Neutral Red uptake as a measure for the number of cells present in the well. a Osteogenic differentiation of hMSCs in
osteogenic differentiation medium supplemented with or without 125 ng/ml BMP2, 2 ng/ml TGFβ1, 10 μg/ml insulin, 500 μM IBMX, or 10−7 M
rosiglitazone. ALP activity is significantly higher (p < 0.001) in medium with BMP2 and TGFβ in the presence of IBMX than in the absence of IBMX.
b Osteogenic differentiation of hMSCs in adipogenic differentiation medium supplemented with or without 125 ng/ml BMP2 and 2 ng/ml TGFβ1,
and following omission of 10 μg/ml insulin, 500 μM IBMX, or 10−7 M rosiglitazone. ALP activity is significantly higher (p < 0.01) in medium with all
supplements than in the absence of IBMX. c Effect of PGE2, added at the indicated nanomolar concentrations, on osteogenic differentiation of
hMSCs in osteogenic differentiation medium. A comparison is made with the effects of BMP2 (125 ng/ml), TGFβ (2 ng/ml), and IBMX (500 μM).
Enhancement of ALP activity is significant (p < 0.05) at concentrations of 10 nM PGE2 and above. d Effect of BMP2 (125 ng/ml) and TGFβ (2 ng/ml) on
total Ca2+ deposition (μg) in a six-well plate well (10 cm2) by hMSCs, cultured for 13 days in either osteogenic or adipogenic differentiation
medium. Ca2+ deposition is significantly enhanced by BMP2 alone in osteogenic differentiation medium (p < 0.01) and by BMP2 + TGFβ in
adipogenic differentiation medium (p < 0.05). ALP alkaline phosphatase, BMP bone morphogenetic protein, IBMX 3-isobutyl-1-methylxanthine,
PGE2 prostaglandin E2, TGFβ transforming growth factor beta
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as supplements BMP2 and combinations of IBMX and
TGFβ. Untreated cells at day 0 served as the control ex-
periment. In order to verify the extent of differentiation of
the cells used for the microarray experiments, we used
real-time PCR to measure mRNA expression levels of the
osteoblast-specific alkaline phosphatase (ALPL) gene and
of the adipocyte-specific adiponectin (ADIPOQ) gene, a
target gene of the adipogenic master gene PPARG. This
analysis was carried out 7 days after incubation with
BMP2 (B), BMP2 + TGFβ (BT), BMP2 + IBMX (BI), or
BMP2 + TGFβ + IBMX (BTI). Figure 4a shows that under
these conditions IBMX, in combination with TGFβ, en-
hanced ALPL expression. No inhibitory effect of TGFβ
was observed on bone cell differentiation, in agreement
with the data of Fig. 2b. ADIPOQ expression was strongly
enhanced upon IBMX addition, but reduced again to very
low levels in the additional presence of TGFβ (Fig. 4b).
These data confirm that, at the gene expression level,
TGFβ induces a switch from adipocytes to osteoblasts.
The data from the 54 microarray samples were normal-
ized using RMA [15] followed by LIMMA [16] statistical
analysis to identify differentially expressed genes and func-
tional enrichment analysis using DAVID [17, 18]. From
the 54,675 probes on the chip, 7755 probes appeared dif-
ferentially expressed at any time point or treatment, com-
pared with the t = 0 control, based on a q value of 10−5
and a minimum log2-fold change of 1. Our primary inter-
est was to identify genes that controlled the TGFβ-
induced switch from adipogenic to osteogenic differenti-
ation. In the current experiment, genes downregulated by
TGFβ are potentially involved in adipogenic differenti-
ation and genes upregulated by TGFβ in osteogenic differ-
entiation. A comparison between the samples BTI and BI
resulted in 2911 differentially expressed probes at any
time point, of which 1176 probes (735 genes) were differ-
entially expressed at the early time points (days 1 and 2),
when cells become committed for lineage specific differ-
entiation. Extending the log2-fold change from 1 to a
minimum of 2 resulted in a reduction of the number of
differentially expressed genes between BTI and BI to 109,
Fig. 3 IBMX controls HDAC5 expression levels in hMSCs. a HDAC5
mRNA levels, relative to that of the housekeeping gene RSP27A, of
hMSCs incubated for 24 hours (white shading) or 48 hours (black
shading) in proliferation medium (C), adipogenic differentiation
medium (A), osteogenic differentiation medium (O), osteogenic
differentiation medium supplemented with 125 ng/ml BMP2 and 2 ng/
ml TGFβ (OBT), and osteogenic differentiation medium supplemented
with 125 ng/ml BMP2, 2 ng/ml TGFβ, and 500 μM IBMX (OBTI). Data
expressed as percentage of the expression levels at time zero. Results
represent the mean and standard deviation of duplicate experiments.
Indicated significance levels are relative to expression in control samples
(C) at 24 or 48 hours, respectively. b Immunoblot for protein
expression of HDAC5 in hMSCs, 5 days after incubation in the
indicated media. Expression of α-tubulin was used as a loading
control. *p < 0.05; **p < 0.01; ***p < 0.001. HDAC histone deacetylase
Fig. 4 Expression of osteogenic and adipogenic markers in hMSCs
under conditions used for gene expression microarray analysis. Cells
were incubated for 7 days in adipogenic differentiation medium
containing 50 ng/ml BMP2 (B-7), 50 ng/ml BMP2 + 5 ng/ml TGFβ
(BT-7), 50 ng/ml BMP2 + 500 μM IBMX (BI-7), and 50 ng/ml BMP2 +
5 ng/ml TGFβ + 500 μM IBMX (BTI-7). Untreated cells at day zero
(C-0) were used as a control. a mRNA expression of the bone marker
ALP (ALPL), relative to that of the housekeeping gene RSP27A.
Results represent the mean and standard deviation of duplicate
experiments. Both BI-7 (p < 0.05) and BTI-7 (p < 0.01) are significantly
higher than B-7 and BT-7. b mRNA expression of the fat marker
adiponectin (ADIPOQ), relative to that of the housekeeping gene
RSP27A. Results represent the mean and standard deviation of
duplicate experiments. BI-7 is significantly higher than both B-7 and
BTI-7 (p < 0.01)
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of which 25 were established drug targets according to the
DrugBank database (www.drugbank.ca). Visual inspection
of the time course for expression of these genes identified
nine genes which showed the desired dynamics; that is,
modulation at early time points and higher expression in
BI than in BTI, as presented in Fig. 5.
Analysis of adipogenic differentiation inhibitors
For the thus identified target genes, as presented in Table 1,
we tested whether commercially available inhibitors could
block the adipogenic differentiation of hMSCs under condi-
tions similar to those used for the microarray analysis. We
first confirmed the established observation that adipogenic
differentiation does not occur in the absence of a PPARG
agonist, such as rosiglitazone, and therefore an antagonist
of this receptor was not further tested. We did, however,
also observe that inhibitors of ADAMTS5 and AKR1B10
prevented adipogenic differentiation of hMSCs, while in-
hibitors of AGTR1, BDKRB2, and KCNK3 were without ef-
fect. Earlier studies in the literature have already indicated
that inhibitors of metalloproteinases, including Batimastat,
have a negative influence on adipogenic differentiation [23],
but this is the first report for an inhibitory effect of an aldo-
keto reductase inhibitor.
Figure 6a shows the effect of Batimastat on adipogenic
and osteogenic differentiation of hMSCs under the ex-
perimental conditions used for the microarray analysis.
TGFβ and DMSO, as a vehicle for Batimastat, were used
as a positive and a negative control. The data show that
Batimastat inhibits adipogenic differentiation in a dose-
dependent manner but, in contrast to TGFβ, this inhib-
ition does not result in a concomitant enhancement of
osteogenic differentiation. A similar observation was
made for the AKR1B10 inhibitors Sorbinil (not shown)
and Zopolrestat. The quantitative analysis presented in
Fig. 6b shows that Zopolrestat actively inhibits adipo-
genic differentiation of hMSCs in a dose-dependent
manner, although to a lesser extent than Batimastat.
Discussion
Osteoporosis is a debilitating disease which affects tens
of millions of people worldwide. Postmenopausal women
are particularly at risk of developing this disease, since
reduced estrogen activity enhances the bone-resorbing
Fig. 5 Time course for expression of the nine selected genes for their involvement in adipogenic differentiation. Expression levels were obtained
from analysis of the 50 ng/ml BMP2 and 250 μM IBMX (BI, white circle) and 50 ng/ml BMP2, 5 ng/ml TGFβ, and 250 μM IBMX (BTI, black square)
chips. Expression levels are indicated on a log2 scale. BMP bone morphogenetic protein, IBMX 3-isobutyl-1-methylxanthine, TGFβ transforming
growth factor beta
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activity of osteoclasts. Additionally, aging in general
results in a significant reduction in the number and
function of bone-forming osteoblasts [24]. Treatment of
patients with osteoporosis may include hormone re-
placement therapies and the use of bisphosphonates to
inhibit the activity of osteoclasts. Moreover, vitamin D3
or parathyroid hormone can be prescribed to enhance
new bone formation [25]. Recent years have seen an in-
creasing interest in the interaction between fat and bone
cells in the bone marrow. Patients suffering from osteo-
porosis show an increased number of adipocytes in their
bone marrow, concomitant with a reduction in the pool
of hMSCs that are able to differentiate into osteoblasts
[2, 3]. In addition, adipokines secreted by these adipo-
cytes may further enhance osteoclast activity [26], while
an increasing fat content of the bone marrow may also
impair the bone cell niche required for the functioning
of hematopoietic stem cells [27].
These considerations show that there is great need for
developing drugs that prevent the differentiation of
hMSCs into fat cells and may thereby enhance their dif-
ferentiation into bone cells. Likewise, drugs that prevent
adipogenic differentiation could also be useful in the bat-
tle against obesity. In the present study we have shown
that, under proper in-vitro conditions, TGFβ is able to
stimulate osteogenic differentiation and prevent adipo-
genic differentiation within the same culture. These cul-
ture conditions require not only the presence of DEX
and BMP, but also of a cAMP-enhancing stimulus such
as IBMX or PGE2. Because of its strong side effects
TGFβ is not suited for in-vivo applications, but our
results show that the current in-vitro system can be used
for identifying genes whose expression is repressed
following a TGFβ-induced switch from adipogenic to
osteogenic differentiation of hMSCs. By concentrating
on those genes for which FDA-approved drugs are avail-
able, we have identified nine potential genes that could
be tested for inhibition of adipogenic differentiation of
hMSCs. Using this approach we have identified the
nuclear hormone receptor PPARG, the metalloprotein-
ase ADAMTS5, and the aldo-keto reductase AKR1B10
as potential drug targets for treatment of osteoporosis
and obesity.
TGFβ is a highly pleiotropic cytokine which plays an
important role in many physiological processes, as well
as in cancer [28, 29]. Because of its strong inhibitory
effect on the immune system, systemic treatment with
TGFβ is not considered a realistic option, except for
protection against autoimmune diseases [30]. Studies in
laboratory animals have shown that TGFβ treatment can
result in skin fibrosis and toxicity, without displaying
significant antitumor effects [31, 32]. Local injection of
TGFβ into the knee joint has been shown to enhance
cartilage integrity, leading to prevention of osteoarthritis
Table 1 Selected genes involved in adipogenic differentiation
Gene name Protein function Inhibitor Effect
ADAMTS5 Metalloproteinase Batimastat Positive
AGTR1 Angiotensin II receptor Losartan Negative
AKR1B10 Aldo-keto reductase Zopolrestat Positive
BDKRB2 Bradykinin receptor B2 Icatibant Negative
CXCL12 Chemokine SDF-1 (Not tested) (Not tested)
KCNK3 Potassium channel Doxapram Negative
PPARG Nuclear receptor GW9662 Positive
PRKAR2B cAMP protein kinase (Not tested) (Not tested)
VCAM1 Vascular cell adhesion (Not tested) (Not tested)
Table presents the HUGO name, function, commercially available drug, and
status of experimentally observed effects
positive observed effect, negative no observed effect
Fig. 6 Effect of selected inhibitors on adipogenic differentiation of
hMSCs. a Effect of Batimastat, added at the indicated concentrations
to hMSCs in adipogenic differentiation medium, on adipogenic
(upper panel; Oil Red O (ORO) staining, day 9) and osteogenic
differentiation (lower panel; alkaline phosphatase (ALP) staining, day
7). No addition (Cont), TGFβ (2 ng/ml), and DMSO (0.1 %; used as a
solvent for Batimastat) were used as controls. b Inhibition of
adipogenic differentiation by Batimastat (Bat) and Zopolrestat (Zop),
added at the indicated micromolar concentrations. Quantitative Oil
Red O staining was measured at 530 nm on hMSCs treated for
9 days with adipogenic differentiation medium. TGFβ (5 ng/ml) was
used as a control. Significance levels are indicated relative to
untreated controls (Cont). *p < 0.05; **p < 0.01; ***p < 0.001. DMSO
dimethyl sulfoxide, TGFβ transforming growth factor beta
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[33]. Our present study shows that the effect of TGFβ
on osteogenic differentiation of hMSCs strongly de-
pends on the culture conditions. In osteogenic differen-
tiation medium TGFβ inhibits bone cell differentiation,
while it promotes this process in adipogenic differenti-
ation medium. Since the local conditions in the fatty
bone marrow of osteoporosis patients are not well
defined, it is difficult to predict whether injection of
TGFβ will result in a net enhancement or a decrease of
functional osteoblast cells. Furthermore, current clinical
trials directed towards TGFβ are aimed at inhibiting its
activity in cancer patients, since overactivation of
TGFβ-induced pathways have been associated with
cancer progression [28, 29].
Among the genes that were downregulated at early time
points following TGFβ treatment of hMSCs in adipogenic
differentiation medium is PPARG. This observation is not
unexpected, since ligand-induced activation of PPARG
(e.g., by rosiglitazone) is known to be essential for adipo-
genic differentiation. We have studied the role of PPARG
in this process not by using the PPARG-specific antagonist
GW9662 (see Table 1), but by omitting rosiglitazone from
the culture medium, which resulted in a complete block
of fat cell formation (data not shown). The promoting role
of PPARG agonists in obesity is well established, but on
the contrary these hormones have been shown to be clin-
ically active as antidiabetic drugs [34]. Because of these
multiple faces of PPARG, inhibition of this nuclear hor-
mone receptor does not seem an attractive approach for
the prevention of fatty bone marrow formation in osteo-
porosis patients.
The second gene for which inhibitors were found to pre-
vent fat cell differentiation is ADAMTS5, a disintegrin and
metalloproteinase with thrombospondin motifs [35]. Its
main function is the cleavage of the aggrecan core protein,
in which it appears more efficient than other matrix metal-
loproteinases (MMPs) [36]. Recent studies on Adamts5–/–
mice, however, have indicated that ADAMTS5 may not
responsible for aggrecan proteolysis, but instead regulates
glucose uptake by mediating the endocytotic trafficking of
LRP1 and GLUT4 [37]. Other studies have shown that de-
letion of active ADAMTS5 prevents cartilage degradation
in a murine model of osteoarthritis [38]. Batimastat and
the related drug Marimastat have primarily been developed
as antineoplastic drugs. They prevent angiogenesis by
blocking metalloproteinases including MMPs and ADAM
family members [39]. Both drugs performed poorly in
clinical trials on metastatic breast cancer patients [40] and
were therefore never marketed. Previous studies have
shown that Batimastat blocks the enzymatic activity of
MMP2 and MMP9, and prevents the differentiation of
mouse 3T3-F442A preadipocytes into fat cells [23, 41].
Our present results show that Batimastat also prevents
adipogenic differentiation of hMSCs. Long-term studies
on Batimastat and Marimastat in humans are lacking and
therefore it cannot be concluded whether these drugs
present a real potential for the treatment of patients with
osteoporosis or obesity. MMPs are not only involved in
cancer progression, but also play an important role in
inflammation and immunity [42]. Multiple natural com-
pounds have been identified which seem to block MMP
activity [43]. It will be interesting to test the effects of
these compounds, some of which are used as food supple-
ments, in relation to osteoporosis and obesity.
In this study we have made the novel observation that
inhibitors of aldo-keto reductases prevent adipogenic dif-
ferentiation of hMSCs. AKR1B10, which was downregu-
lated by TGFβ in our studies, is particularly active on lipid
substrates. It plays an important role in the reduction of
retinaldehyde to retinol, as well as in the lipid modifica-
tion of the K-Ras oncogene. In humans, this gene is par-
ticularly expressed in the intestine, adrenal gland, and
liver. Inhibition of AKR1B10 prevents the outgrowth of
pancreatic carcinoma cells by modulating the Ras pathway
[44, 45]. Moreover, expression of AKR1B10 is considered
to be a tumor marker for NSCLC [46] and liver tumors
[47]. To the best of our knowledge, a role of AKR1B10 in
adipogenic differentiation has not yet been studied. How-
ever, an RNA-mediated knockdown study has indicated
that AKR1B10 is an important regulator of fatty acid bio-
synthesis in human RAO-3 breast cancer cells [48].
AKR1B10 is structurally very similar to AKR1B1, and
many inhibitors of AKR1B1 also bind AKR1B10. These
include the drugs Sorbinil and Zopolrestat, which have
been used in the present study. These and related FDA-
approved drugs are used particularly for treatment of
patients with diabetic polyneuropathy [49]. They do so
by inhibiting the metabolism of glucose by the so-called
polyol pathway, which converts glucose into sorbitol.
This reduced sugar accumulates in the cell and, as a
result of osmotic stress, induces microvascular damage
to the retina, kidney, and nerves. Although each of these
drugs has its specific adverse effects, including rash,
toxicity, and hypersensitivity reactions, at least some of
them were well tolerated in clinical trials lasting more
than a year [49]. However, no long-term beneficial
effects of these drugs were observed in diabetes patients.
More recently, AKR1B1 inhibitors have also been tested
as anticancer drugs [50]. So far, no reports have been
made in the literature on the effects of aldo-keto reduc-
tase inhibitors on patients with osteoporosis or obesity.
Similar to observations for MMPs, multiple naturally
occurring inhibitors for aldo-keto reductases have been
identified, particularly from plant tissue [51, 52]. Feeding
mice with the most potent of these natural AKR1B
inhibitors, bisdemethoxycurcumin, has been shown to
reduce particularly the incidence of intestinal cancer.
Interestingly, some of these natural compounds inhibit
van Zoelen et al. Stem Cell Research & Therapy  (2016) 7:123 Page 10 of 13
not only AKR1B members but also MMPs. In ongoing
research we are testing the effects of these natural com-
pounds on fat cell differentiation. These studies may
provide a lead towards the further development of more
optimized compounds which specifically prevent adipo-
genic differentiation in vivo.
TGFβ is generally considered to be an inhibitor of bone
cell differentiation, but our current results show that in the
presence of cAMP-enhancing agents TGFβ is able to
promote osteogenic differentiation. PGE2, which has been
shown to raise cAMP levels in hMSCs [53], is known to
stimulate osteogenesis upon short-term admission in vivo
[54], but it is unclear whether PGE2 exerts its action by
preventing TGFβ from inhibiting bone formation. Kim et
al. [12] have shown that cAMP-activated protein kinases
play a central role in the choice between osteogenic and
adipogenic differentiation of hMSCs, but again no correl-
ation was made with the activity of TGFβ. Our present
data are summarized in Fig. 7, which show that PPARG,
the nuclear transcription factor essential for adipogenic
commitment, is inhibited by TGFβ, which consequently
suppresses the maturation to adiponectin and Oil Red O-
positive fat cells. On its own TGFβ suppresses the activity
of RUNX2, the nuclear transcription factor essential for
osteogenic commitment by a SMAD3/HDAC5-mediated
mechanism [20], resulting in impaired maturation to ALP
and matrix mineralization-positive bone cells. However, in
the presence of IBMX, which strongly represses HDAC5,
TGFβ becomes an activator of RUNX2-mediated osteo-
genesis. Obviously, the TGFβ-mediated inhibition of adipo-
genesis is not HDAC5 sensitive.
Using our gene expression microarray analysis we have
identified novel inhibitors of adipogenic differentiation.
We thereby focused on genes which were differentially
expressed on days 1 and 2 following TGFβ treatment.
This time frame corresponds with the upregulation of
commitment genes for adipogenic differentiation such as
PPARG, as shown in Fig. 5. Genes differentially expressed
at later time points were particularly involved in fatty acid
metabolism (data not shown). Figure 6a shows that under
the experimental conditions tested inhibitors of these adi-
pogenic commitment genes did not promote osteogenic
differentiation to the same extent as TGFβ. The possibility
should therefore be considered that within 24–48 hours
the cells have already undergone an irreversible commit-
ment towards either adipogenic or osteogenic differenti-
ation. In that respect it may be interesting to study
whether TGFβ added at later time points can still promote
cells under adipogenic differentiation conditions to be-
come osteoblasts. Alternatively, the possibility should be
considered that under high cAMP conditions TGFβ is able
to stimulate specific pathways leading to osteogenic differ-
entiation. Our current results showing that, in the pres-
ence of cAMP-enhancing agents, TGFβ is able to prevent
the formation of fat cells and promote the formation of
bone cells have been obtained on commercially available
mesenchymal stem cells from bone marrow of healthy
human donors. Given the observation that patients suffer-
ing from osteoporosis show an increased number of adi-
pocytes in their bone marrow, it will be interesting to
carry out similar experiments with mesenchymal stem
cells from such patients. This may indicate if this aberrant
pattern of differentiation results from intrinsic changes in
their stem cells or from an altered microenvironment in
their bone marrow.
Conclusions
Our data show that in the presence of cAMP-enhancing
agents TGFβ stimulates the ability of hMSCs to differ-
entiate into bone cells, while impairing their ability to
Fig. 7 Overview of signaling pathways activated in hMSCs by TGFβ in the absence and presence of IBMX: adipogenic differentiation (left) and
osteogenic differentiation (right). For details, see text. BMP bone morphogenetic protein, HDAC histone deacetylate, IBMX 3-isobutyl-1-methylxanthine,
TGFβ transforming growth factor beta
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differentiate into fat cells. Under these conditions TGFβ
treatment results in a reduced expression of genes which
contribute to adipogenic differentiation, including PPARG,
ADAMTS5, and AKR1B10. Since FDA-approved drugs are
available for these genes, they are potential targets for treat-
ment of patients suffering from osteoporosis or obesity.
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